MetLife Investment Advisors LLC Increases Stake in Aimmune Therapeutics Inc (AIMT)

MetLife Investment Advisors LLC grew its position in Aimmune Therapeutics Inc (NASDAQ:AIMT) by 55.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 31,568 shares of the biotechnology company’s stock after purchasing an additional 11,222 shares during the period. MetLife Investment Advisors LLC’s holdings in Aimmune Therapeutics were worth $861,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in AIMT. Rhumbline Advisers increased its holdings in shares of Aimmune Therapeutics by 25.0% in the second quarter. Rhumbline Advisers now owns 41,731 shares of the biotechnology company’s stock valued at $1,122,000 after purchasing an additional 8,348 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Aimmune Therapeutics by 9.1% in the second quarter. Bank of New York Mellon Corp now owns 171,766 shares of the biotechnology company’s stock valued at $4,619,000 after purchasing an additional 14,283 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in shares of Aimmune Therapeutics by 12.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 207,255 shares of the biotechnology company’s stock valued at $5,574,000 after purchasing an additional 23,678 shares during the period. BlackRock Inc. increased its holdings in shares of Aimmune Therapeutics by 18.4% in the second quarter. BlackRock Inc. now owns 3,643,840 shares of the biotechnology company’s stock valued at $97,984,000 after purchasing an additional 565,410 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Aimmune Therapeutics in the second quarter valued at about $1,568,000. 75.02% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Aimmune Therapeutics in a research note on Friday, November 23rd. ValuEngine downgraded Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. BidaskClub upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Credit Suisse Group set a $40.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 19th. Finally, Roth Capital set a $80.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 13th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $48.90.

Shares of AIMT stock opened at $25.63 on Monday. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -9.82 and a beta of -0.07. Aimmune Therapeutics Inc has a 12-month low of $21.38 and a 12-month high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.03. As a group, equities analysts forecast that Aimmune Therapeutics Inc will post -3.6 EPS for the current fiscal year.

In other Aimmune Therapeutics news, insider Jayson Donald Alexander Dallas purchased 3,650 shares of the stock in a transaction on Monday, November 19th. The shares were bought at an average price of $27.56 per share, for a total transaction of $100,594.00. Following the completion of the transaction, the insider now owns 63,600 shares of the company’s stock, valued at approximately $1,752,816. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “MetLife Investment Advisors LLC Increases Stake in Aimmune Therapeutics Inc (AIMT)” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2019/01/14/metlife-investment-advisors-llc-increases-stake-in-aimmune-therapeutics-inc-aimt.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Read More: How to Use a Moving Average for Trading 

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit